{'fraction_non_alphanumeric': 0.019807583474816072, 'fraction_numerical': 0.001697792869269949, 'mean_word_length': 5.646616541353383, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Potential use of auxiliary labels to promote patient awareness of pharmacogenetic testing.

In this paper, we consider the advantages and disadvantages of using an auxiliary label for pharmacogenetic (PGx) testing to promote patient awareness. Auxiliary labels are typically used to highlight key information about medication use or risks. If information about PGx is displayed prominently on the medication container, this may motivate patients to consult with a pharmacist and/or contact their health provider to inquire about testing. Through a simple label, the patient becomes empowered to ask and acquire the knowledge that may improve treatment decisions and outcomes. With the increased understanding of the impact of genetic variants on drug response and subsequent development of clinical PGx tests [1], increasing patient awareness and understanding about testing will be important, yet challenging. Numerous patient education resources are available to help patients learn about their prescribed medications. However, some patients struggle to identify and understand their medication regimens and risks due to inadequate health literacy and numeracy, language, reduced cognitive ability in elderly patients, medication complexity and polypharmacy [2–4]. Patients are likely to be unfamiliar with PGx testing. Furthermore, the complexity of test outcomes and recommendations, as well as the limited amount of information about testing currently available for patients, may pose challenges to patients’ understanding. Thus, new educational strategies or integration into existing strategies are needed to promote patient awareness of PGx testing. In this paper, we consider the use of auxiliary labels as a tool to promote patient awareness of PGx testing.